Datopotamab Deruxtecan in Advanced or Metastatic Non–Small Cell Lung Cancer with Actionable Genomic Alterations: Results from the Phase II TROPION-Lung05 Study

The TROPION-Lung05 Phase II trial evaluated the safety and clinical activity of datopotamab deruxtecan in patients with advanced NSCLC with actionable genomic alterations progressing on or after targeted therapy and platinum-based chemotherapy.